Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
Launched by PFIZER · Feb 15, 2018
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
The primary research question is to evaluate the apixaban utilization according to the approved SPAF indication and recommendations by EMA.
In addition a comparison with a cohort of NVAF patients treated with VKA, dabigatran and rivaroxaban for the SPAF indication will also be performed.
Objective 1: To characterize patients using apixaban according to demographics, comorbidity, risk of thromboembolic events (CHADS2 and CHA2DS2-Vasc scores), risk of bleeding events (HAS-BLED score), comedications and compare it with the profile of patients treated with VKA, dabigatran and rivaroxaban.
Ob...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients more than 18 years-old.
- • 2. Patients diagnosed with NVAF registered in primary care according to ICD-10.
- • 3. Patients initiating apixaban (naïve or VKA experienced), VKA (naïve or VKA experienced), dabigatran or rivaroxaban for the SPAF indication.
- • 4. Continuous enrolment in the 12 months pre-index.
- Exclusion Criteria:
- • 1. Patients with valvular heart disease (ICD 10: I05.0-I05.09, I08.0-I08.9) including patients with mitral prosthetic valves.
- • 2. Lost to follow-up (e.g. transfer to primary care center non-ICS).
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, Cataluña, Spain
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials